Name | cyclovirobuxine D |
Synonyms | NSC91722 Cyclovirobuxine CYCLOVIROBUXINE Cyclovirobuxin D CYCLOVIROBUXINE D cyclovirobuxine D Cyclovirobuxin D(Bebuxine) Cyclovirobuxin D(Bebuxine,Cyclovirobuxine D, NSC 91722 ) 9,19-CYCLOPREGNANE-3,20-DIAMINE,N,N',4,4,14-PENTAMETHYL-, (3,5,20S)- 9,19-Cyclopregnan-16-ol, 4,4,14-trimethyl-3,20-bis(methylamino)-, (3β,5α,16α,20S)- (3beta,5alpha,9beta,16alpha,20S)-4,4,14-trimethyl-3,20-bis(methylamino)-9,19-cyclopregnan-16-ol (3beta,5alpha,9xi,10xi,14xi,16alpha,20S)-4,4,14-trimethyl-3,20-bis(methylamino)-9,19-cyclopregnan-16-ol |
CAS | 860-79-7 |
InChI | InChI=1/C26H46N2O/c1-16(27-6)21-17(29)14-24(5)19-9-8-18-22(2,3)20(28-7)10-11-25(18)15-26(19,25)13-12-23(21,24)4/h16-21,27-29H,8-15H2,1-7H3/t16-,17+,18-,19-,20-,21-,23+,24-,25+,26-/m0/s1 |
Molecular Formula | C26H46N2O |
Molar Mass | 402.66 |
Density | 0.9815 (rough estimate) |
Melting Point | 220-221 °C (decomp)(Solv: acetone (67-64-1)) |
Boling Point | 524.75°C (rough estimate) |
Flash Point | 34.1°C |
Solubility | Soluble in chloroform, soluble in methanol or ethanol, slightly soluble in acetone, slightly soluble in water. |
Vapor Presure | 6.66E-12mmHg at 25°C |
Appearance | Colorless needle crystal |
pKa | 15.12±0.70(Predicted) |
Storage Condition | 2-8℃ |
Refractive Index | 1.5300 (estimate) |
MDL | MFCD00468040 |
Physical and Chemical Properties | White crystalline powder, soluble in chloroform, methanol, ethanol, derived from the bark of the leaves of the plant. |
In vitro study | Cyclovirobuxine D increases the activity of cardiomyocytes injured by oxidation or hypoxia. It can significantly reduce the infarct size caused by coronary artery ligation in rats. In addition, Cyclovirobuxine D protects rat aortic endothelial cells from damage caused by hypoxia and enhances nitric oxide (NO) release from endothelial cells. Cyclovirobuxine D promotes the utilization of Ca(2) in cells and prevents the loss of Ca(2), which may be the potential mechanism of its protective effect on heart failure. |
In vivo study | Cyclovirobuxine D reduces the weight of venous thrombi in rats. In anaesthetized pigs, Cyclovirobuxine D elicits an initial effect of coronary vasodilation, which involves a mechanism related to nitric oxide release in endothelial cells. In addition, Cyclovirobuxine D was able to ameliorate myocardial infarction-induced heart failure in rats in vivo. LD50: mice 8.9 mg/kg (intravenous injection),9.2 mg/kg (intraperitoneal injection),293 mg/kg (Gavage). |
Safety Description | 24/25 - Avoid contact with skin and eyes. |
HS Code | 29420000 |
Toxicity | LD50 oral in mouse: 293mg/kg |
Reference Show more | 1. Zengxia, Zhimin, Wang He, Qiu Chengjie, Zhao Yanan, Cao Yingjie, Jiejin Hong. Effects of cyclovirobuxinum D on L-type calcium channels in atrial myocytes of rats injured by H_2O_2 [J]. Guangdong Medical Journal, 2020,41(16):1631-1636. 2. [IF = 3.417] Lingqi Zhou et al."Cyclovirobuxine D inhibitors cell propagation and migration and induced interactions in human gliobastoma multiforma and low-grade glioma." Oncol Rep. 2020 Mar;43(3):807-816 |
biological activity | cyclovirobuxind (Bebuxine, CVB-D) is an active compound extracted from Buxus microphylla and used in the treatment of acute myocardial ischemia. |
Use | xanthin has antiarrhythmic effect. for content determination/identification/pharmacological experiments. Pharmacological Efficacy: with qi and blood circulation, Tongluo analgesic pharmacological effects. Clinically, it is mainly used for the treatment of chest pain caused by Qi stagnation and blood stasis, pulse generation, coronary heart disease and angina pectoris. |